KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2025)

Recursion Pharmaceuticals' Assets Average history spans 5 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 32.12% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 32.12%, while the annual FY2025 figure was $1.5 billion, 39.03% up from the prior year.
  • Assets Average reached $1.4 billion in Q4 2025 per RXRX's latest filing, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.4 billion in Q4 2025 to a low of $285.3 million in Q1 2021.
  • Average Assets Average over 5 years is $797.0 million, with a median of $665.6 million recorded in 2023.
  • Peak YoY movement for Assets Average: soared 135.69% in 2022, then dropped 8.81% in 2024.
  • A 5-year view of Assets Average shows it stood at $634.5 million in 2021, then increased by 3.46% to $656.4 million in 2022, then decreased by 2.16% to $642.3 million in 2023, then surged by 69.33% to $1.1 billion in 2024, then soared by 32.12% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).